WACKER BIOSOLUTIONS under New Leadership
Susanne Leonhartsberger will leave the company at her own request at the end of 2024.
Advertisement
Mathias Wiedemann will take over as president of WACKER BIOSOLUTIONS on January 1, 2025. He succeeds Susanne Leonhartsberger, who will leave the company at her own request at the end of 2024.

Mathias Wiedemann is to become head of the WACKER BIOSOLUTIONS division of Wacker Chemie AG on January 1, 2025.
Quelle: Wacker Chemie AG
“I am delighted that we have been able to recruit Mathias Wiedemann, an outstanding colleague from our own midst, to head our biotech division. I wish him every success in his new role,” says WACKER CEO Christian Hartel. Wiedemann previously headed WACKER’s POLYMERS business in the USA. His new assignment sees him returning to Munich. “BIOSOLUTIONS offers exciting products and services. I look forward to meeting this challenge. We are pursuing ambitious growth targets with a great team. Our goal is to generate one billion euros in sales in 2030,” explains Wiedemann.
Mathias Wiedemann studied engineering and business administration at the University of Bremen, where he earned his doctorate in engineering on a scholarship from WACKER BIOSOLUTIONS. He joined WACKER as a project engineer in 2011. After holding several specialist and managerial positions in Germany and abroad, he was most recently responsible for POLYMERS’ business in North and Central America. In May 2024, Wiedemann was also appointed CFO of Wacker Chemical Corporation.
Susanne Leonhartsberger took charge of the BIOSOLUTIONS division in 2020. She joined WACKER in 2001 and has been instrumental in developing BIOSOLUTIONS in various functions both in Germany and elsewhere. Development milestones under her leadership include the establishment of an mRNA competence center in Halle/Saale, Germany, in the context of the pandemic-preparedness agreements with the German government. “Susanne Leonhartsberger has taken BIOSOLUTIONS a decisive step forward on its growth path,” emphasizes Hartel. “On behalf of the entire Executive Board, I would like to thank her for her commitment and dedication. We wish her all the best for the future.”
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

DMC Biotechnologies announces Dr. Jim Flatt as CEO - DMC seeking to transform how the world makes chemicals

Merck: New CEOs for Life Science and Healthcare business sectors and New Chief People Officer - Appointment of three internal senior executives ensures strategic continuity with a new era of leadership

CureVac appoints new CEO - Dr. Franz-Werner Haas to complete tenure as CEO by March 31, 2023

LenioBio announces new CEO - Founder will be stepping down as CEO

T-CURX announces senior leadership appointments - T-CURX completes formation of highly experienced clinical team to rapidly advance clinical translation of its next-generation CAR-T cell therapies

Samanta Cimitan Appointed Chief Executive Officer (CEO) at Celonic

BioGaia appoints Theresa Agnew as new CEO

EVIDENT Corporation Appoints New CEO and COO

Danaher appoints Christopher Riley to Executive Vice President for Biotechnology

Biotage AB appointment of new CEO

Dr. Christine Munz becomes CEO at Eppendorf - Dr. Wilhelm Plüster completes term in office as planned
